Jason Campagna, MD, PhD
President of R&D and Chief Medical Officer
Jason brings more than 20 years of leadership experience in early- and late-stage clinical development across leading biopharmaceutical companies. Most recently, he served as Chief Medical Officer at Q32 Bio, where he oversaw clinical strategy and development.
Previously, Jason held multiple leadership roles at Intercept Pharmaceuticals, including Head of the Global MASH Program, which led to the first-ever NDA submission to the FDA for a therapy targeting MASH. He later served as Chief Medical Officer with responsibility for the company’s PBC franchise, global MASH program, and broader pipeline strategy.
Before joining Intercept, Jason held positions of increasing responsibility at The Medicines Company, including as Senior Vice President and Health Science Lead for Surgery and Perioperative Care.